Integrated Diagnostics Holdings plc
Integrated Diagnostics Holdings plc (IDGXF) Stock Overview
Explore Integrated Diagnostics Holdings plc’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
164.5M
P/E Ratio
15.99
EPS (TTM)
$0.04
ROE
0.24%
IDGXF Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Integrated Diagnostics Holdings plc (IDGXF) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.43.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 15.99 and a market capitalization of 164.5M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Integrated Diagnostics Holdings plc, a consumer healthcare company, provides various medical diagnostics services to patients. It offers approximately 2,000 diagnostic test services, including immunology, microbiology, hematology, endocrinology, clinical chemistry, molecular biology, cytogenetics, histopathology, and radiology. The company operates in Egypt, Jordan, Sudan, and Nigeria. As of December 30, 2021, it operated a network of 452 branch labs. The company was founded in 1979 and is headquartered in Saint Helier, Jersey.
Hend El Sherbini
6,309
12 Castle Street, Saint Helier
2019